<DOC>
	<DOCNO>NCT02452983</DOCNO>
	<brief_summary>This study investigate effect sertraline people low-risk myelodysplastic syndrome ( MDS ) . It hop sertraline decrease disease progression reduce need blood transfusion .</brief_summary>
	<brief_title>Sertraline Treatment Low-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>This pilot study investigate clinical benefit four 28-day cycle sertraline low-risk MDS patient . Participants receive 100mg oral sertraline daily . The study also evaluate potential associate biological mechanism action .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Diagnosis Very Low Low risk MDS define IPSSR confirm bone marrow aspirate biopsy ( Blast count must &lt; 20 % ) Hemoglobin &lt; 11 g/dL , transfusion dependency . Platelet count &lt; 100,000/mm3 Absolute Neutrophil Count ( ANC ) &lt; 1000/mm3 Life expectancy 12 month great ECOG Performance status 0 3 Age â‰¥ 18 year Willing use medically acceptable method birth control study 28 day discontinue study treatment All subject must inform investigational nature study must sign give write informed consent accordance institutional federal guideline Both men woman member race ethnic group Previous exposure 5AC ( azacitidine ) decitabine Use antidepressants sertraline within 6 week OR use paroxetine , fluoxetine , citalopram within 3 month prior registration Active case ( within past 12 month ) depressive disorder , manic episode , and/or anxiety require active treatment SSRI . Patients treat SSRI nonpsychiatric indication allow , go appropriate washout . Previous concurrent malignancy , except treat basal cell squamous cell cancer skin , treat situ cervical cancer , treat lobular ductal carcinoma situ one breast , cancer patient diseasefree least 5 year Actively receive chemoimmunotherapy Evidence active infection Treatment steroid immunosuppressive therapy cyclosporine , tacrolimus , antithymocyte globulin ( ATG ) within 6 month registration Platelet transfusion within 8 week registration . Platelet count &lt; 20,000/mm3 within 14 day registration . Active treatment growth factor erythropoietin stimulate agent ( ESA ) , granulocyte colonystimulating factor ( GCSF ) , thrombopoietin stimulate factor within 8 week registration Treatment investigational agent within 4 week registration History autoimmune disease include rheumatoid arthritis , systemic lupus sarcoidosis History allergic reaction attribute compound similar chemical biologic composition sertraline Known history splenomegaly Pregnant nursing woman exclude study Sertraline Class C agent potential teratogenic abortive effect . Because unknown potential risk adverse event nurse infant secondary treatment mother sertraline , breast feeding discontinue . HIV : Given high risk Immune thrombocytopenic purpura , HIV associate neutropenia combination antiretroviral therapy , patient know HIV exclude potential pharmacokinetic interaction sertraline . Any condition illness , Investigator 's opinion , would place subject unacceptable risk he/she participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Hematologic disease</keyword>
	<keyword>Cytopenias</keyword>
	<keyword>Bone marrow disease</keyword>
	<keyword>Preleukemia</keyword>
</DOC>